^
Association details:
| Biomarker: | NTRK2 fusion |
|---|---|
| Cancer: | Peritoneal Cancer |
| Drug: | Vitrakvi (larotrectinib) (TrkA receptor inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Acceptable Recurrence Therapies for…Peritoneal Cancer: Useful in Certain Circumstances...Targeted Therapy (single agents)...Entrectinib or Larotrectinib (for NTRK gene fusion-positive tumors)